News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Immunitybio (IBRX) has been one of a handful of top investments that I have been confidently adding to during the small and mid-cap care sell-off taking place over the course of 2021. I believe the market will continue to overlook the intrinsic value of the merged company and its potential to remodel the paradigm in numerous indications. Sadly, it looks as if the market hasn't even acknowledged Anktiva’s recent bladder cancer data that is undeniably the best data ever produced in that indication. For that reason, I will continue to remain nimble with my position while remaining extremely bullish on IBRX in anticipation the market will recognize the opportunity and will be forced to price IBRX at a proper valuation. I intend to provide some background on Anktiva and review its bladder cancer data. In addition, I discuss why I think the market is allowing the share price to continue to deteriorate. Finally, I discuss a key bullish point for the longs.

ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price Oct. 12, 2021 2:10 AMImmunityBio, Inc. (IBRX) Summary ImmunityBio’s share price bearish trend continues since its merger despite Anktiva moving closer to a BLA submission in BCG-unresponsive non-muscle-invasive carcinoma in situ bladder cancer. This extensive sell-off is demoralizing and is inflicting max pain on longs. I believe the sell-off is being fueled by several sources, none of which are running empty. The company’s cytokine infusion protein and a novel interleukin-15 “IL-15” superagonist complex, Anktiva, could become a blockbuster product in the coming years. Regardless of the sell-off, I remain bullish on IBRX at these prices and will continue to follow my current strategy.

Nur indirekt, da auch der Immun Marker PD-L1 genannt wird. Wird aber kaum etwas mit dem Kursanstieg zu tun haben.

Hat die Studie was mit uns zu tun? Ist das der Grund für den heutigen Anstieg?

New treatment kills head and neck cancer in trails https://www.theguardian.com/society/2021/oct/11/new-cancer-treatment-destroys-tumours-in-terminally-ill-finds-trial Die Test werden von Bristol Myers Squibb finanziert.

Die letzte Transaktion war ein Kauf von der Freundin unseres CEOs, Richard Adcock - 1930 Shares für 16.995$

ImmunityBio (NASDAQ:IBRX) Insider Trade Frequently Asked Questions WHO IS ON IMMUNITYBIO'S INSIDER ROSTER? The list of insiders at ImmunityBio includes Barry J Simon, Cheryl Cohen, and Richard Adcock.Learn more on IBRX's insiders WHAT PERCENTAGE OF IMMUNITYBIO STOCK IS OWNED BY INSIDERS? 82.80% of ImmunityBio stock is owned by insiders.Learn more on IBRX's insider holdings WHICH IMMUNITYBIO INSIDERS HAVE BEEN BUYING COMPANY STOCK? The following insider purchased ImmunityBio stock in the last 24 months: Richard Adcock ($17,003.30). HOW MUCH INSIDER BUYING IS HAPPENING AT IMMUNITYBIO? Insiders have purchased a total of 1,930 ImmunityBio shares in the last 24 months for a total of $17,003.30 bought. WHICH IMMUNITYBIO INSIDERS HAVE BEEN SELLING COMPANY STOCK? The following insiders have sold ImmunityBio stock in the last 24 months: Barry J Simon ($581,181.56), and Cheryl Cohen ($688,733.88). HOW MUCH INSIDER SELLING IS HAPPENING AT IMMUNITYBIO? Insiders have sold a total of 104,388 ImmunityBio shares in the last 24 months for a total of $1,269,915.44 sold. https://www.marketbeat.com/stocks/NASDAQ/IBRX/insider-trades/?RegistrationCode=SocialMedia-StockTwits&DefaultTab=Insider&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia

National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy Lung-MAP trials are studying how well investigational or new drugs work in non-small cell lung cancer (NSCLC) patients and will study how N-803 (Anktiva) could bolster the current standard of care, checkpoint inhibitors. ImmunityBio’s study will test its IL-15 receptor superagonist complex N-803 (Anktiva) in combination with Merck’s pembrolizumab (Keytruda) in up to 478 second-line patients with tumors that are not targetable with a drug, which accounts for the majority of NSCLC cases. The study is one of the National Cancer Institute’s largest lung cancer clinical trials with more than 700 sites and enrollment is anticipated to begin in Q4 2021. https://ir.immunitybio.com/news-releases/news-release-details/national-cancer-institute-selects-immunitybios-n-803-il-15?field_nir_news_date_value[min]=

Ramaphosa: New cancer & Covid-19 vaccine initiative will be a game-changer for South Africa https://smile904.fm/ramaphosa-new-cancer-covid-19-vaccine-initiative-will-be-a-game-changer-for-south-africa/?app=true

ImmunityBio Plans Trial For Second Covid-19 Shot in South Africa https://www.bnnbloomberg.ca/immunitybio-plans-trial-for-second-covid-19-shot-in-south-africa-1.1658387

3. Quartal 2021 und 1. Quartal 2022 : Quilt 88 - Pancreatic also has a cohort C investigating NCV - Nant Cancer Vaccine. To study the safety and early efficacy signals across multiple tumor types, the company has launched a series of Quantitative Lifelong Trials (QUILT). To date, the NANT Cancer Vaccine has been studied in more than 100 patients across multiple tumor types, including pancreatic, breast, colorectal, and head and neck cancers. Among these studies is QUILT 88, a Phase 2 trial studying the NCV in metastatic pancreatic cancer patients. Enrollment of Cohort C, patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first quarter of 2022. https://ir.immunitybio.com/news-releases/news-release-details/immunitybios-novel-immunotherapy-nant-cancer-vaccine-currently?field_nir_news_date_value[min]=

Lesenswert!

Pancreatic cancer patients from around the world flock to Hoag Hospital for clinical trial https://www.ocregister.com/2021/06/25/pancreatic-cancer-patients-from-around-the-world-flock-to-hoag-hospital-for-clinical-trial/amp/?__twitter_impression=true

Billionaire to back cancer, Covid vaccines in SA (By Antony Sguazzin, Bloomberg 23 Sep 2021  11:51) ImmunityBio company is conducting trials of its Covid-19 vaccine in SA and has held talks with Cape Town’s Biovac Institute to potentially set up vaccine production facilities. South African-born biotech billionaire Patrick Soon-Shiong will announce a plan to transfer technology for the manufacture of Covid-19 and cancer vaccines to the African country. The California-based entrepreneur will make the announcement at 5 p.m. local time Thursday with President Cyril Ramaphosa, the South African presidency said in a statement. Soon-Shiong’s NantWorks has signed a collaboration agreement with the South African government’s Council for Scientific and Industrial Research, the South African Medical Research Council and the Centre for Epidemic Response and Innovation. Three local universities are also party to the agreement. Soon-Shiong, who has a net worth of $11 billion according to the Bloomberg Billionaires Index, was born in the South African coastal town of Gqeberha. He made his fortune after inventing cancer drug Abraxane in the US and has sold two firms for a combined $7.4 billion. His assets include the Los Angeles Times newspaper and a share of the Los Angeles Lakers basketball team. His ImmunityBio Inc. company is conducting trials of its Covid-19 vaccine in South Africa and has held talks with Cape Town’s Biovac Institute to potentially set up vaccine production facilities in the country. https://www.moneyweb.co.za/in-depth/own-your-life/billionaire-to-back-cancer-covid-vaccines-in-sa/